Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation Academic Article uri icon

Overview

MeSH Major

  • Antigens, CD34
  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation
  • Immunosuppressive Agents
  • Leukemia, Myeloid, Acute
  • Lymphocyte Depletion
  • Siblings
  • T-Lymphocyte Subsets

abstract

  • These results suggest that TCD via CD34 selection might lower long-term morbidity as a result of chronic GVHD without negatively impacting relapse rates in patients with acute myeloid leukemia. Additional prospective studies should be undertaken to definitively address the role of TCD in HCT.

publication date

  • September 10, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3434978

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.41.7071

PubMed ID

  • 22869882

Additional Document Info

start page

  • 3194

end page

  • 201

volume

  • 30

number

  • 26